Login to Your Account

U.S. Patent Disclosures

Tuesday, October 18, 2011
Lpath Inc., of San Diego, received U.S. Patent Nos. 8,025,877, and 8,026,342, which claim methods and composition of matter for its anti-sphingosine-1-phosphate antibody, sonepcizumab, the active component in the firm's lead compounds iSONEP and ASONEP.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription